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Scientific Newsfront
Nebulized nitroglycerin in children with pulmonary
hypertension secondary to congenital heart disease
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following changes (mean ±SI; paired ,
statistics): systolic pulmonary artery;
pressure from 68±8 to 53±6 at 10 min
into treatment (P 0.006), mean
pulmonary artery pressure 4 7±4 to
38±4 (P 0.005), heart rate 131±8 to
127±7(P 0.13), systolic blood pressure
85±8 to 88±3 (P 0. 7), mean blood
pressure 59±6 to 63±4 (P 0.5). These
results indicate that nebulized
nitroglycerine may be an effective,
easy to administer, inexpensive, and
safe alternative for treatment of
severe pulmonary hypertension in
cbildren with congenital heart disease,
especially in areas where other
treatments such as extracorporeal
membrane oxygenation or inhaled
nitric oxide are inaccessible.
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Abstract

..

Pulmonary hypertension continues
to be a major cause of morbidity and
mortaUty, despite new treatments.
Since inhaled nitric oxide has been
reported to be effective in some
cases, we investigated using
nebulized nitroglycerine to treat
pulmonary hypertension in children
with congenital heart disease. Four
children (ages 6-72 months) with
severe pulmonary hypertension
secondary to congenital heart
disease (all with membranous
ventricular septal defect, undergoing
cardiac catheterization) were given
3 cc of nebulized normal saline over
10 min as placebo contro~followed
by nebulized nitroglycerine (20}lg/Kg
in 3cc normal saline). Normal saline
administration did not elicit any
change, but nitroglycerine
administration resulted in the
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Introduction
Pulmonary hypertension (PHD
continues to be a major cause of
morbidity and mortality in the
pediatric age group. One common
cause of pulmonary hypertension is
congenital heart disease, unless the
congenital heart lesions are
surgically corrected early in life (1).
Conventional therapy with
mechanical ventilation is not always
effective and use of intravenously
administered vasodilators is limited
because of the systemic effects,
such as hypotension. Extracorporeal
membrane oxygenation (ECMO)
can be effective, but it is invasive
and not feasible in small hospitals
and rural areas. The discovery of
the endothelium-derived relaxing
factor (EDRF, 2) and its identification
as nitric oxide (NO, 3) made it
potentially possible to use inhaled
NO for treatment of persistent
pulmonary hypertension.
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Reports of beneficial effects of
inhaled NO in infants with
persistent PHT (4), as well as in
children with congenital heart
disease (CHD, 5), are promising.
Delivery of inhaled NO, however,
requires special equipment (5,6)
and may also be toxic.
Many rural areas in the U.S. and
the world have no access to either
ECMO or inhaled NO.
Nitrovasodilators are believed to
release NO during their metabolism
(7) and thus their vasodilatory
mechanism is similar to that of NO.
In this study, we sought to
determine if nebulized nitroglycerine
(NTG) can be effective in reducing
pulmonary artery pressure without
significant change in systemic BP in
children with pulmonary
hypertension secondary to CHD.

Methods
This study was approved by the
Research Administration at Zhejiang
Medical University Children's
Hospital and consent was obtained
for each of the four children, ages 6
months to six years. These children
were spontaneously breathing with
uncorrected ventricular septal defect
and severe PHT undergoing
diagnostic cardiac catheterization.
Severe pulmonary hypertension
was defined as pulmonary artery
pressure at least half of systemic
blood pressure (Table 1). Baseline
pulmonary artery pressure, systemic
blood pressure, oxygen saturation,
and heart rate were measured. Each
patient received 3 cc of nebulized
normal saline (NS) as placebo
control and these vital signs were
recorded at 5 min intervals.

Next, each patient received a
dose of 20 g per kilogram body
weight of NTG in total volume of 3
cc NS nebulized and their vital signs
were recorded at 5 min intervals.

Results
Nebulized NS failed to produce
any changes in any of the patients.
Nebulized NTG, on the other hand,
significantly reduced pulmonary
artery pressure without changing the
systemic BP or heart rate (Table 2).
This study was terminated at the
end of the catheterization procedure
with no long-term follow-up.

Discussion
Treatment for severe PHT
continues to be difficult and often is
not successful, despite the promising
role of nebulized NO and ECMO as
well as other treatment modalities.
The fact that the mechanism of
action of nitrovasodilators involves
metabolism to NO led us to
investigate of their potential.
To study the potential benefits of
nebulized NTG on PHT, we selected
four stable patients undergoing a
diagnostic procedure. The lack of
effect of NS eliminated the possibility
of a placebo effect when using NTG.
The significant reduction of both
systolic and mean pulmonary artery
pressures is encouraging, knowing
that patients with uncorrected VSD
tend to have sustained high diastolic
pressure which would not respond
well to any treatment.
Administering nebulized NTG had
no effect on systemic BP or heart rate,
presumably because of the fast local
metabolism and short half-life. This
finding is also promising because of
the limitations of any treatments
associated with systemic effects.

Conclusion
Nebulized NTG appears to be an
effective, easy to administer,
inexpensive and safe alternative for
treatment of severe PHT in children
with CHD, especially in areas where
other treatment modalities such as
ECMO or inhaled NO are inaccessible.

Larger studies on similar patients
;md also on patients with different
etiologies are needed to confirm
our preliminary fmdings.
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